Myriad Genetics, Inc’s filing revealed that its President and CEO DIAZ PAUL J unloaded Company’s shares for reported $0.34 million on Oct 11 ’24. In the deal valued at $22.93 per share,15,000 shares were sold. As a result of this transaction, DIAZ PAUL J now holds 962,378 shares worth roughly $13.3 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, DIAZ PAUL J bought 15,000 shares, generating $343,950 in total proceeds.
Before that, Ancona Margaret bought 11,538 shares. Myriad Genetics, Inc shares valued at $321,019 were divested by the Officer at a price of $27.82 per share.
UBS initiated its Myriad Genetics, Inc [MYGN] rating to a Neutral in a research note published on December 10, 2024; the price target was $18. A number of analysts have revised their coverage, including Leerink Partners’s analysts, who decreased its forecast for the stock in early December from “an Outperform” to “a Market perform”. Morgan Stanley began covering MYGN with “an Equal-weight” recommendation on September 19, 2024. Wells Fargo started covering the stock on August 28, 2024. It rated MYGN as “an Overweight”.
Price Performance Review of MYGN
On Tuesday, Myriad Genetics, Inc [NASDAQ:MYGN] saw its stock fall -2.12% to $13.82. Over the last five days, the stock has lost -9.91%. Myriad Genetics, Inc shares have fallen nearly -27.80% since the year began. Nevertheless, the stocks have fallen -33.37% over the past one year. While a 52-week high of $29.30 was reached on 09/18/24, a 52-week low of $13.92 was recorded on 12/17/24. SMA at 50 days reached $18.53, while 200 days put it at $22.85.
Levels Of Support And Resistance For MYGN Stock
The 24-hour chart illustrates a support level at 13.63, which if violated will result in even more drops to 13.45. On the upside, there is a resistance level at 14.15. A further resistance level may holdings at 14.49. The Relative Strength Index (RSI) on the 14-day chart is 26.41, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.25, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 98.69%. Stochastics %K at 8.57% indicates the stock is a buying.
How much short interest is there in Myriad Genetics, Inc?
A steep rise in short interest was recorded in Myriad Genetics, Inc stocks on 2024-11-29, dropping by -1.09 million shares to a total of 3.39 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-31 was 4.48 million shares. There was a decline of -32.23%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on June 27, 2024 when Scotiabank began covering the stock and recommended ‘”a Sector outperform”‘ rating along with a $29 price target.
